Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Second booster of monovalent or bivalent COVID-19 vaccines in healthy adults
NCT05543356Phase 3Withdrawn
- Sponsor
- Murdoch Children's Research Institute
- Start
- May 2022
- Primary completion
- Jul 2022
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tozinameran, elasomeran and elasomeran + imelasomeran in coronavirus disease 2019 (COVID-19), sponsored by Murdoch Children's Research Institute. Planned start May 2022; status: withdrawn.
02
Drugs
tozinameranelasomeranelasomeran + imelasomeran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05543356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05543356.